Frontiers in Cardiovascular Medicine (Dec 2022)

Histone modification of endothelial-mesenchymal transition in cardiovascular diseases

  • Qiu Jun,
  • Li Youhong,
  • Zhong Yuan,
  • Yang Xi,
  • Bingyu Wang,
  • Sun Xinyi,
  • Yin Fu,
  • Cen Kedan,
  • Jiangfang Lian,
  • Zhou Jianqing,
  • Zhou Jianqing

DOI
https://doi.org/10.3389/fcvm.2022.1022988
Journal volume & issue
Vol. 9

Abstract

Read online

Endothelial-mesenchymal transition (EndMT) is a differentiation process in which endothelial cells lose their own characteristics and acquire mesenchymal-like characteristics, which contributes to the formation and development of atherosclerotic plaques. Until now, there is still a lack of effective measures to treat atherosclerosis (AS), so there is an urgent need to understand the underlying mechanisms of AS. In addition, although various studies have shown that EndMT is involved in the pathological stages of cardiovascular diseases, such as myocardial fibrosis, myocardial hypertrophy, and hypertension, the specific molecular mechanisms driving EndMT are still in the exploratory stage. In this review, we review the role of histone modifications (methylation, demethylation and acetylation, deacetylation) on EndMT in cardiovascular disease, aiming to target histone-modifying enzymes to guide cardiovascular disease therapy.

Keywords